Bradanicline
Identification
- Generic Name
- Bradanicline
- DrugBank Accession Number
- DB06090
- Background
Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7). Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 361.445
Monoisotopic: 361.179026993 - Chemical Formula
- C22H23N3O2
- Synonyms
- Bradanicline
- External IDs
- TC 5619
- TC-5619
Pharmacology
- Indication
Investigated for use/treatment in neurologic disorders.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7). The α7 NNR is associated with a variety of biological functions. In particular, the α7 NNR has been shown in animal studies to be an essential regulator of both inflammation arising from injury or infection and cognitive functions. α7 NNR plays a role in protecting neuronal cells from deterioration and death, a process known as neuroprotection.
Target Actions Organism UNeuronal acetylcholine receptor subunit alpha-7 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Bradanicline hydrochloride D266D7TY9B 1111941-90-2 ISPRRZDPZDVHLE-OZYANKIXSA-N Bradanicline tosylate 3821HT7KCR 1111942-11-0 YDJXUVIIXSFVOJ-OZYANKIXSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzofurans
- Sub Class
- Not Available
- Direct Parent
- Benzofurans
- Alternative Parents
- 2-heteroaryl carboxamides / Quinuclidines / Furoic acid and derivatives / Aralkylamines / Benzenoids / Pyridines and derivatives / Piperidines / Heteroaromatic compounds / Amino acids and derivatives / Trialkylamines show 7 more
- Substituents
- 2-heteroaryl carboxamide / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzofuran / Carboxamide group / Carboxylic acid derivative show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UM3821998K
- CAS number
- 639489-84-2
- InChI Key
- OXKRFEWMSWPKKV-GHTZIAJQSA-N
- InChI
- InChI=1S/C22H23N3O2/c26-22(20-13-17-5-1-2-6-19(17)27-20)24-21-16-7-10-25(11-8-16)18(21)12-15-4-3-9-23-14-15/h1-6,9,13-14,16,18,21H,7-8,10-12H2,(H,24,26)/t18-,21+/m0/s1
- IUPAC Name
- N-[(2S,3R)-2-[(pyridin-3-yl)methyl]-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-2-carboxamide
- SMILES
- [H][C@@]1(CC2=CC=CN=C2)N2CCC(CC2)[C@@]1([H])NC(=O)C1=CC2=C(O1)C=CC=C2
References
- General References
- Not Available
- External Links
- PubChem Compound
- 25147644
- PubChem Substance
- 175427053
- ChemSpider
- 26366935
- BindingDB
- 50393247
- ChEMBL
- CHEMBL1258006
- ZINC
- ZINC000064540331
- Wikipedia
- Bradanicline
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Attention Deficit Hyperactivity Disorder (ADHD) 2 2 Completed Treatment Chronic Cough (CC) 1 2 Completed Treatment Cognitive Dysfunctions / Negative Symptoms / Schizophrenia 1 2 Completed Treatment Cognitive Dysfunctions / Schizophrenia 1 1 Completed Diagnostic Alzheimer's Disease (AD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0559 mg/mL ALOGPS logP 2.74 ALOGPS logP 2.36 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 14.57 Chemaxon pKa (Strongest Basic) 7.44 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 58.37 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 103.6 m3·mol-1 Chemaxon Polarizability 40.05 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9929 Blood Brain Barrier + 0.9384 Caco-2 permeable - 0.5681 P-glycoprotein substrate Substrate 0.6162 P-glycoprotein inhibitor I Inhibitor 0.7817 P-glycoprotein inhibitor II Inhibitor 0.87 Renal organic cation transporter Inhibitor 0.5813 CYP450 2C9 substrate Non-substrate 0.8777 CYP450 2D6 substrate Non-substrate 0.5 CYP450 3A4 substrate Substrate 0.6271 CYP450 1A2 substrate Inhibitor 0.5739 CYP450 2C9 inhibitor Inhibitor 0.5 CYP450 2D6 inhibitor Inhibitor 0.7462 CYP450 2C19 inhibitor Inhibitor 0.7294 CYP450 3A4 inhibitor Non-inhibitor 0.6073 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.9138 Ames test Non AMES toxic 0.6482 Carcinogenicity Non-carcinogens 0.9429 Biodegradation Not ready biodegradable 0.9964 Rat acute toxicity 2.5836 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7514 hERG inhibition (predictor II) Inhibitor 0.6864
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0009000000-4663a1c76238165e5dd5 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0109000000-21626bdaa806bd415ce9 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0029000000-485cb9cef5ef425b6b42 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03dl-2539000000-c36877c6c298b00e58b6 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00kg-5911000000-e26eca8e3836b054781f Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-014l-3913000000-9d7fa0ad7e62bcc6bd30 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 197.2872334 predictedDarkChem Lite v0.1.0 [M-H]- 180.40456 predictedDeepCCS 1.0 (2019) [M+H]+ 198.3178334 predictedDarkChem Lite v0.1.0 [M+H]+ 182.80013 predictedDeepCCS 1.0 (2019) [M+Na]+ 198.4652334 predictedDarkChem Lite v0.1.0 [M+Na]+ 188.71265 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
- Gene Name
- CHRNA7
- Uniprot ID
- P36544
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-7
- Molecular Weight
- 56448.925 Da
Drug created at November 18, 2007 18:29 / Updated at February 13, 2024 02:57